Summary
This is a reissue with no substantive policy changes for MA06.023c (Nerve Fiber Density Testing). The policy was last reviewed and reissued on 03/04/2026 per Independence Blue Cross's annual review process. The coverage criteria, experimental/investigational designations, and affected CPT codes (11102-11107) remain unchanged from the original 01/01/2024 effective date.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 6 steps
01No immediate action required.
02This reissue contains no policy changes.
03Billing teams should verify that claims for nerve fiber density testing (CPT 11102-11107) are currently being submitted with appropriate medical necessity documentation demonstrating: (1) symptoms of painful sensory neuropathy, (2) absence of predisposing neuropathy disorders, (3) normal physical examination (no large-fiber neuropathy findings), and (4) normal EMG/NCS studies.
04Continue applying existing coverage criteria.
05Sweat gland nerve fiber density measurements remain experimental/investigational and non-covered.
06Monitor for the next annual reissue (expected 2027).
Codes mentioned
111021110311104111051110611107
Original notice
MA06.023c, Nerve Fiber Density Testing
medpolicy.ibx.com · Always check the source before changing claims.